LP
SYRE icon

LMR Partners’s Spyre Therapeutics SYRE Stock Holding History

LMR Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,093
Closed -$421K – 1311
2024
Q1 		$421K Buy
+11,093
New +$321K ﹤0.01% 784
2022
Q4 		– Sell
-769
Closed -$10K – 1265
2022
Q3 		$10K Hold
769
– – ﹤0.01% 1190
2022
Q2 		$10K Buy
+769
New +$26.9K ﹤0.01% 1256

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

LMR Partners's SYRE Position: Q2 2024 in Review

LMR Partners sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 11,093 shares — an estimated $421K sold.

LMR Partners first reported a position in SYRE in Q2 2022 and held it in 3 quarters. The position peaked at $421K in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • LMR Partners reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 11,093 Spyre Therapeutics shares in Q2 2024, an estimated $421K.
  • LMR Partners first reported a position in Spyre Therapeutics in Q2 2022 and held it in 3 quarters.
  • LMR Partners's Spyre Therapeutics position peaked at $421K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.